Loading...
Drug Pricing Investigation: Amgen--Enbrel and Sensipar
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Citations
Altmetric:
Abstract
The House Committee on Oversight and Reform issued a Staff Report on the pricing practices of Amgen, Inc. concerning the drugs Enbrel and Sensipar. The report includes recommendations.
Date
2020-10-01
Document Type
House Staff Report
Serial Number
Document Length
41 pages
Congress
116
Relation
DOI
Keywords
Staff Reports, House
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Cited Hearings
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Lowering Prescription Drug Prices: Deconstructing the Drug Supply Chain," 116th Cong., H.Hrg. 116-32, (2019, May 9)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• House Committee on Energy and Commerce, Subcommittee on Health, hearing on "Lowering Prescription Drug Prices: Deconstructing the Drug Supply Chain," 116th Cong., H.Hrg. 116-32, (2019, May 9)